Published Online:9 May 2012https://doi.org/10.4155/fmc.12.41
Abstract
The farnesoid X receptor (FXR) is a bile sensor that acts in coordination with other nuclear receptors to regulate essential steps in bile acid uptake, metabolism and excretion. In addition, FXR is an ancillary receptor involved in lipid and glucose homeostasis. Steroidal and non-steroidal FXR ligands are currently available. Both groups have shown limitations in the preclinical studies regarding absorption, metabolism, specificity of target and intrinsic toxicity. FXR ligands endowed with agonistic activity are under development for the treatment of cholestatic liver diseases, including primary biliary cirrhosis and metabolic disorders linked to insulin resistance. Despite the fact that results from preclinical models are encouraging, targeting FXR holds potential for side effects (i.e., impaired cholesterol disposal and cholestasis). Thus, results from FXR gene-ablated mice and mice administered an FXR antagonist support a role for FXR antagonists or modulators (i.e., FXR agonists that selectively activate specific subsets of FXR target genes in a tissue) or co-regulator-specific manner.
Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest
References
- 1 Forman BM, Goode E, Chen J et al. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell81,687–693 (1995).
- 2 Wang H, Chen J, Hollister K, Sowers LC, Forman BM. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol. Cell3,543–553 (1999).
- 3 Fiorucci S, Mencarelli A, Distrutti E, Palladino G, Cipriani S. Targeting farnesoid-X-receptor: from medicinal chemistry to disease treatment. Curr. Med. Chem.17,139–159 (2010).
- 4 Fiorucci S, Donini A, Distrutti E, Santucci L. Targeting FXR for liver and metabolic indications. Trends Mol. Med.13,298–309 (2007).
- 5 Chiang JY. Bile acids: regulation of synthesis. J. Lipid Res.50,1955–1966 (2009).
- 6 Jonker JW, Liddle C, Downes M. FXR and PXR: potential therapeutic targets in cholestasis. J. Steroid Biochem. Mol. Biol. (2012) (In Press).
- 7 Geier A, Wagner M, Dietrich CG, Trauner M. Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration. Biochim. Biophys. Acta1773,283–308 (2007).
- 8 Cai SY, Xiong L, Wray CG, Ballatori N, Boyer JL. The farnesoid X receptor FXRalpha/NR1H4 acquired ligand specificity for bile salts late in vertebrate evolution. Am. J. Physiol. Regul. Integr. Comp. Physiol.293,R1400–R1409 (2007).
- 9 Christian M, White R, Parker MG. Metabolic regulation by the nuclear receptor corepressor RIP140. Trends Endocrinol. Metab.17,243–250 (2006).
- 10 Pellicciari R, Costantino G, Fiorucci S. Farnesoid X Receptor: from structure to potential clinical applications. J. Med. Chem.48,5383–5403 (2005).
- 11 Pellicciari R, Ellicciari R, Costantino G et al. Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure–activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid. J. Med. Chem.47,4559–4569 (2004).
- 12 Wang S, Lai K, Moy FJ, Bhat A, Hartman HB, Evans MJ. The nuclear hormone receptor farnesoid X receptor (FXR) is activated by androsterone. Endocrinology147,4025–4033 (2006).
- 13 Akwabi-Ameyaw A, Bass JY, Caldwell RD et al. Conformationally constrained farnesoid X receptor (FXR) agonists: naphthoic acid-bile acids and analogs of GW 4064. Bioorg. Med. Chem. Lett.18,4339–4343 (2008).
- 14 Suzuki T, Tamehiro N, Sato Y et al. The novel nompounds that activate farnesoid X receptor: the diversity of their effects on gene expression. J. Pharmacol. Sci.107,285–294 (2008).
- 15 Soisson SM, Parthasarathy G, Adams AD et al. Identification of a potent synthetic FXR agonist with an unexpected mode of binding and activation. Proc. Natl Acad. Sci. USA105,5337–5342 (2008).
- 16 Dussault I, Beard R, Lin M et al. Identification of gene-selective modulators of the bile acid receptor FXR. J. Biol. Chem.278,7027 (2003).
- 17 Evans MJ, Mahaney PE, Zhang S et al. Abstract 584: a synthetic farnesoid X receptor agonist protects against diet-induced dyslipidemia. Circulation116,106 (2007).
- 18 Houck KA, Borchert KM, Hepler CD et al. T0901317 is a dual LXR/FXR agonist. Mol. Genet. Metab.83,184 (2004).
- 19 Corpechot C, Carrat F, Bahr A, Chretien Y, Poupon RE, Poupon R. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology128,297–303 (2005).
- 20 Stedman C, Liddle C, Coulter S et al. Benefit of farnesoid X receptor inhibition in obstructive cholestasis. Proc. Natl Acad. Sci. USA103,11323–11328 (2006).▪▪ Study supporting the development of an farnesoid X receptor (FXR) antagonist in the treatment of cholestasis.
- 21 Mennone A, Soroka CJ, Cai SY et al. Mrp4-/- mice have an impaired cytoprotective response in obstructive cholestasis. Hepatology43,1013–1021 (2006).
- 22 Renga B, Migliorati M, Mencarelli A et al. Farnesoid X receptor suppresses constitutive androstane receptor activity at the multidrug resistance protein-4 promoter. Biochim. Biophys. Acta157–165 (2011).
- 23 Mason A, Luketic V, Lindor K et al. Farnesoid-X receptor agonists: a new class of drugs for the treatment of PBC? An international study evaluating the addition of INT-747 to ursodeoxycholic acid. J. Hepatol.52,S1–S2 (2010).▪▪ First report to describe the effects of an FXR agonist in the treatment of primary biliary cirrhosis patients.
- 24 Fiorucci S, Cipriani S, Baldelli F, Mencarelli A. Bile acid-activated receptors in the treatment of dyslipidemia and related disorders. Prog. Lipid Res.49,171–185 (2010).▪ Summarizes the role of FXR- and bile acid-activated receptors in metabolic diseases.
- 25 Sirvent A, Verhoeven AJ, Jansen H et al. Farnesoid X receptor represses hepatic lipase gene expression. J. Lipid. Res.45,2110–2115 (2004).
- 26 Sirvent A, Claudel T, Martin G et al. The farnesoid X receptor induces very low density lipoprotein receptor gene expression. FEBS Lett.566,173–177 (2004).
- 27 Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, Gonzalez FJ. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell102,731–744 (2000).
- 28 Chennamsetty I, Claudel T, Kostner KM et al. Farnesoid X receptor represses hepatic human APOA gene expression. J. Clin. Invest. doi:10.1172/JCI45277 (2011) (Epub ahead of print).
- 29 Rizzo G, Disante M, Mencarelli A et al. The farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function in vivo. Mol. Pharmacol.70,1164–1173 (2006).
- 30 Mencarelli A, Renga B, Distrutti E et al. Antiatherosclerotic effect of farnesoid X receptor. Am. J. Physiol. Heart Circ. Physiol.296,H272–H281 (2009).
- 31 Hartman HB, Gardell SJ, Petucci CJ et al. Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-/- and apoE-/- mice. J. Lipid. Res.50,1090–1100 (2009).
- 32 Prawitt J, Abdelkarim M, Stroeve JH et al. Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity. Diabetes60(7),1861–1871 (2011).
- 33 Watanabe M, Horai Y, Houten SM et al. Lowering bile acid pool size with a synthetic FXR agonist induces obesity and diabetes through reduced energy expenditure. J. Biol. Chem.286(30),26913–26920 (2011).▪▪ Adverse metabolic effects could develop in response to chronic use of FXR agonists in the treatment of rodent model of obesity.
- 34 Renga B, Mencarelli A, Vavassori P et al. The bile acid sensor FXR regulates insulin transcription and secretion. Biochim. Biophys. Acta1802,363–372 (2010).
- 35 Popescu IR, Helleboid-Chapman A et al. The nuclear receptor FXR is expressed in pancreatic beta-cells and protects human islets from lipotoxicity. FEBS Lett.584,2845–2851 (2010).
- 36 Farrell GC. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology43,S99–S112 (2006).
- 37 Belfort R, Harrison SA, Brown K et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N. Engl. J. Med.355,2297–2307 (2006).
- 38 Cipriani S, Mencarelli A, Chini MG et al. The bile acid receptor GPBAR-1 (TGR5) modulates integrity of intestinal barrier and immune response to experimental colitis. PLoS ONE6,e25637 (2011).
- 39 Henry RR, Mudaliar S, Morrow L et al. Farnesoid-X receptor agonists: a new therapeutic class for diabetes and fatty liver disease? The first FXR therapeutic study in diabetes. Presented at: Annual Meeting of the American Diabetes Association. Chicago, IL, USA, 6–9 June 2007.
- 40 Sanyal AJ, Mudaliar S, Henry RR et al. A new therapy for nonalcoholic fatty liver disease and diabetes? Int-747 – the first FXR hepatic therapeutic study. Hepatology50,389A–390A (2009).▪▪ First report describing the potential therapeutic role of an FXR agonist in the treatment of non-alcoholic fatty acid liver disease patients.
- 41 Burris TP, Montrose C, Houck KA et al. The hypolipidemic natural product guggulsterone is a promiscuous steroid receptor ligand. Mol. Pharmacol.67,948–954 (2005).
- 42 De Marino S, Ummarino R, D’Auria MV et al. Theonellasterols and conicasterols from Theonella swinhoei. Novel marine natural ligands for human nuclear receptors. J. Med. Chem.54,3065–3075 (2011).▪ Study reporting the identification of theonellasterol G as the first FXR modulator and pregnane X receptor ligand so far identified, highlighting its pharmacological potential in the treatment of liver disorders, such as obstructive cholestasis.
- 43 Sepe V, Bifulco G, Renga B et al. Discovery of sulfated sterols from marine invertebrates as a new class of marine natural antagonists of farnesoid-X-receptor. J. Med. Chem.54,1314–1320 (2011).
- 44 Renga B, Mencarelli A, D’Amore C et al. Discovery that theonellasterol a marine sponge sterol is a highly selective FXR antagonist that protects against liver injury in cholestasis. PLoS ONE7(1),e30443 (2012).▪▪ First demonstration that specific FXR antagonists exist and could be of pharmacological relevance.
